Investigating a new treatment for wet age-related macular degeneration
Official title: Mechanistic study and therapeutic application of AIBP in AMD
Funded at Baylor College of Medicine · NIH-11018605 · Data updated 2026-11-12
This study is looking at a new way to help older adults with a serious eye condition called choroidal neovascularization, which can cause vision loss, by testing a protein that might improve treatment for those who haven't had success with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2023 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $400,150 |
| NIH project number | 5R01EY033805-03 |
| Project ID | NIH-11018605 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with wet age-related macular degeneration who have not responded well to existing anti-VEGF therapies.
✕Less likely to help
Patients with dry age-related macular degeneration or those who have not been diagnosed with any form of AMD may not benefit from this research.
What this research studies
This research focuses on developing a new therapeutic approach for treating choroidal neovascularization (CNV), a severe form of age-related macular degeneration (AMD) that can lead to blindness in older adults. The study aims to explore the role of a protein called AIBP, which may help improve treatment outcomes for patients who do not respond well to current therapies. By enhancing cholesterol efflux and reducing inflammation, AIBP could potentially offer a more effective alternative to existing anti-VEGF treatments. Patients will be evaluated to determine how AIBP can be integrated into their treatment plans to address the limitations of current therapies.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients suffering from wet age-related macular degeneration.
How similar studies have gone: Previous research has shown promise in using alternative therapies for AMD, but the specific application of AIBP in this context is relatively novel.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Fu, Yingbin — Baylor College of Medicine
- Study coordinator: Fu, Yingbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.